However, Humira may be preferred due to the ease of administration. Both Remicade and Humira have equal effictiveness. For ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

AbbVie will clearly fight to keep its top-selling Humira (adalimumab ... became more likely after advisers to the US Food and Drug Administration voted unanimously in favour of approving ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by the Food and Drug Administration (FDA). As a quirky ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

Biosimilars reference originator biologics such as Humira. To gain approval by the the Food and Drug Administration, biosimilars must demonstrate that they are highly similar in molecular ...

From the biologics’ first US Food and Drug Administration (FDA) approval in 2002 until 2023, Humira generated $187bn in revenues for AbbVie. Speaking at the JP Morgan Healthcare Conference 2025 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...